64% 34% FY15 at Apollo Hospitals* 250, ,000+ 3,200,000+ 5, , ,000+ 1, , ,000+ Chemotherapy Sittings 7,207 6,200+

Transcription

1 June 25, 2015

2 2

3 3

4 4

5 ` 7,207 2,008 9, FY10 FY11 FY12 FY13 FY14 FY15 20,265 26,054 31,475 37,687 43,842 51, % 28.60% 20.80% 19.70% 16.30% 18.12% 3,013 4,190 5,131 6,082 6,724 7,347 EBITDA Margin 14.90% 16.10% 16.30% 16.10% 15.30% 14.19% Profit After Tax (PAT) 1,376 1,839 2,194 3,044 3,168 3, % 7.10% 7.00% 8.10% 7.20% 6.56% Net Worth 16,776 19,238 25,194 27,641 29,955 32,443 Total Loans 9,132 9,585 8,183 12,179 13,601 20,142 Cash and Cash Equivalents 3,117 2,664 3,588 6,842 4,151 4,833 Gross Revenue(` mn) (3) Gross Revenue($ mn) 6 14 YoY Growth EBITDA 64% 6, ,000+ PAT Margin 3,400+ (2) across 21 states 34% 2% FY15 at Apollo Hospitals* 1,822 Health Insurance (AHEL stake 10.2%) Primary Clinics Sugar Clinics Birthing centres CRADLE Day Care Centres Shareholding(1): Promoters (34.4%), FIIs & FCBs (55.6%), MF/FI/IC (2.0%), Others (8.0%) Market capitalization of ` 190,490 mn(4) and Debt to Equity ratio of 0.52x(1) (1) As on 31st Mar (4) NSE Closing price on 31st Mar 2015 Source: Company audited financials and Q4FY15 Earnings Update. # All financial are for fiscal year (FY) ended March 31. (3) Fx used: US$1= ` 63. Source: Frost & Sullivan 350,000+ 3,200, ,000 Admissions Out-Patients Preventive Health Checks 11,000+ 5, ,000+ Heart Surgeries Joint Replacements Neuro Surgical Operations 500 1, Robotic Surgeries Kidney Transplants Liver Transplants Countries Medical Value Travel Bone Marrow Transplants Radiotherapy Sessions 155, ,000+ Chemotherapy Sittings * FY15 info for owned hospitals only. Does not include managed hospitals 5

6 * # of Beds: 5,100 # of Hospitals: 54 # of Beds: 9,215 # of Hospitals: 55 # of Beds: 2,078 # of Hospitals: 15 # of Beds: 7,452 # of Hospitals: 29 # of Beds: 5,118 # of Hospitals: 15 # of Beds: 1,103 # of Hospitals: 7 # of Beds: 2,016 # of Hospitals: 10 # of Beds: 1,250 # of Hospitals: 1 Capacity Beds Operational No. of Hospitals 7,207 2,008 9,215 6,321 2,008 8, , , ,198 7, ,138 6, , , ,207 4, , Category Wise Owned Managed Grand Total Cluster Wise (Owned) Chennai Hyderabad Kolkata Delhi Bangalore Ahmedabad Tamilnadu (outside Chennai) Bhubaneswar Other India Grand Total Maturity Wise (Owned) > 5 years 3-5 years 1-3 years < 1 year Grand Total Owned Beds CAGR (FY05-15) 9.2% Source: Company Reports, CRISIL Research # Beds as on 31st March * Fortis corporate presentation as of April 2015, publicly available on Fortis Healthcare Ltd. s website. Source: Company MIS Reports, 6

7 7

8 Apollo Day Care Surgery facility for minor surgeries requiring short stay. Hospital at Karaikudi, Tamil Nadu 2013 Hospitals in Vanagaram (Chennai), Jayanagar (Bengaluru) & Trichy 2015 Hospitals in Nashik, Nellore, Women & child centers at Karapakkam & SMR, OMR Perungudi 2011 Apollo Institute of Robotic Surgery launched - the first robotic centre in Tamil Nadu 2012 Placed order for Proton therapy equipment for Cancer treatment 2013 Apollo Health City, Hyderabad performs Minimally Invasive Knee Replacement (Resurface) Surgery using OrthoGlide Medial Knee system FY ,215 beds 1,822 stores Revenues 51,785 mn. 8

9 9

10 10

11 In order to meet the global median of 30 beds per 10,000 population, India will need to invest over ` 14 trillion ($230 bn) Source: CRISIL Research 11

12 12

13 13

14 14

15 15

16 Human Sigma Guest Relation Apollo has adopted the engagement Pathway for Voice of Customer (VOC) Partnered with Gallup to benchmark e-customer feedback with best in class hospitals globally In-house framework captures VOC from Interactions and converts them into Qualitative and quantitative feedback for quick follow-up action Awarded Best Innovation in service delivery In 2013 by AIMA & Hospitals Management Awards 1st in India to adopt Human Sigma by mapping customer and employee engagement to the Gallup S Methodology Ranked this year among top 37 companies that partner with Gallup This recognises exceptional leadership that understands that engaging employees drives real business outcomes Apollo now among globally recognised organisation for mastering how to engage workforce to deliver sustainable growth Admissions Service Excellence Tender Loving Care Core training module for all nurses Inspires the conversion of daily interactions into memorable experiences, resulting in enhanced courtesy index for nursing Tender Loving Care (TLC) Training for frontline staff TLC acknowledge as Best Training Initiative in Healthcare at Asian Learning & Development Leadership Awards In Dubai in 2013 Minimises waiting time for planned admissions Dedicated rooming experience that orients patients and attendees to various hospitals services Discharge Post-discharge calls to patients for suggestions and feedback 72 hours after discharge Speedy discharge summary for planned discharges 16

17 17

18 Healthcare services: Improvement in operating metrics Strong continued revenue growth in mature clusters New Hospitals driving substantial revenue growth through quick ramp up Standalone Pharmacies: Revenue growth and margin improvement Standalone pharmacies reported a positive EBITDA for each of the last five years FY11, FY12, FY13, FY14 & FY15 All stores are in the growth phase with relatively mature stores growing at a consistent rate with increasing EBITDA margins improvement in first year store performance due to better ramp-up and lower losses 18

19 19

20 20

21 India s largest organized pharmacy retail chain with a network of 1,822 stores. Asset light business model with an established track record Presence in metro centers such as Hyderabad, Chennai, Bengaluru, Pune, Ahmedabad and NCR regions Offers a wide range of medicines and surgical products, hospital consumables and over-the-counter products Own brand private labels (FMCG & OTC drugs) constitutes over 6% of FY14 turnover. Target to increase to 20% in next 5 years Introduced generic and in-house brands (Private Labels) Consistent growth in standalone pharmacy revenue Calibrated rollout: 190 stores opened in FY15, 129 stores opened in FY14, 139 stores opened in FY13, 165 stores opened in FY12, 150 in FY11 and 166 in FY10 Increased penetration of private label sales Integrate supply chain network and optimize inventory levels Emphasis on margin improvement Mature cohort of pre-2008 stores have achieved 5.9% EBITDA margins in FY15 Positive overall EBITDA margin FY 11, FY 12, FY13, FY14 & FY15 Regulatory Update: In September 2012, the Central Government approved the DIPP proposal to permit 51% FDI in multi-brand retail, subject to certain conditions 21

22 FY 15: financial performance ` ` FY 14 FY 15 yoy (%) Revenue 38,616 45, % Income from Operations Operative Expenses 20,019 24, % Add: Share of JVs Employee Expenses 6,102 7, % Total Revenues Administrative & Other Expenses 6,357 7, % EBITDA 32,478 39, % margin(%) 6,139 6,781 Total Expenses EBITDA margin (%) 15.9% 10.5% -113 bps 14.8% Depreciation 1,291 1,580 EBIT 4,848 5,200 margin (%) 12.6% 22.4% 7.3% 11.3% -123 bps EBIT margin (%) 48, % 2,730 3, % 43,842 51, % 6,724 7, % 11.5% 3,168 margin (%) 7.2% -4.3% Total Debt Other Income/ Exceptional item * % Profit Before Tax 4,202 4, % Cash & Cash equivalents (includes investment in liquid funds) Profit After Tax 3,307 3,466 margin (%) 8.6% 14.2% -115 bps 5, % 10.1% -141 bps 3, % 6.6% -66 bps 20,142 4, % 7.5% -102 bps 14.6% 12.8% 33,205 40,703 Revenues of ` 45,928 mn, 18.9% yoy growth EBITDA at ` 6,781 mn, 10.5% yoy growth (1) 41,113 Profit After Tax 833 Capital Employed yoy (%) 5, (1) FY % Financial Expenses ROCE (Annualized) FY 14 Revenue growth of 18.1% from ` 43,842 mn in FY 14 to ` 51,785 mn in FY 15 EBIT at ` 5,200 mn, 7.3% yoy growth Consolidated EBITDA grew by 9.3% % from ` 6,724 mn in FY 14 to ` 7,347 mn in FY 15 Higher Depreciation due to application of higher depreciation rates as per the New Companies Act & New Units Nashik and Women & Child, OMR PAT at ` 3,466 mn, 4.8% yoy growth Consolidated PAT grew 7.3% from ` 3,168 mn in FY14 to ` 3,399 mn in FY15 Capital employed for the calculation of ROCE does not include Capital Work in progress on new hospital expansion projects of ` 5,122 mn for FY15 and ` 4,810 mn for FY14 & investments in mutual funds and associates Previous year figures have been reworked/regrouped/rearranged and reclassified wherever necessary to conform to the requirement of revised Schedule VI format JVs include Ahmedabad 50%, Kolkata 50%,PET CT 50%, Apollo Munich 10.23%, Quintiles 40%, Apollo Lavasa 37.50%, Future Parking Pvt Ltd 49% and Apokos Rehab Pvt Ltd 50% 22

23 FY 15: financial performance ` ` Healthcare services (Existing) Revenue Standalone Total Healthcare Services (Existing) New Hospitals 17,726 45,928 30,483 6, ,781 7, % 3.3% 14.8% 23.4% 4, ,200 5, % 2.2% 11.3% 18.3% New Hospitals Healthcare services (Total) SAP 26,435 1,767 28,202 EBITDA 6,276 (75) margin (%) 23.7% EBIT 5,111 margin (%) 19.3% SAP Munich (AHEL stake 10%) AHLL (incl. Cradle) Consolidated 1,767 17, ,074 51,785 (75) (292) 7, % 1.3% % 0.3% FY 15 (300) (300) 14.2% (435) 5, % FY 14 Revenue 24, ,968 13,648 38,616 28, , ,842 EBITDA 5,900 (210) 5, ,139 6,688 (210) 449 (30) (172) 6,724 margin (%) 24.1% 22.8% 3.3% 15.9% 23.6% EBIT 4,838 4, ,848 5,330 margin (%) 19.8% 18.0% 2.5% 12.6% 18.8% (333) 3.3% (333) % (37) (257) 5, % 11.5% YoY Growth Revenue 8.2% 232.7% 13.0% 29.9% 18.9% 7.7% 232.7% 29.9% 21.0% 44.4% 18.1% EBITDA 6.4% NA 9.0% 29.4% 10.5% 6.5% NA 29.4% NA NA 9.3% EBIT 5.6% NA 6.8% 13.7% 7.3% 4.6% NA 13.7% NA NA 3.6% 23

24 Total(5) Particulars FY 14 FY 15 No. of Operating beds 5,811 6, , ,547 Inpatient volume Outpatient volume(3) 1,132,618 1,244,192 Chennai cluster yoy (%) FY 14 FY 15 1,264 1, % 75,931 81, % 351, ,931 yoy (%) FY 14 FY % 51,048 51, % 152, ,717 yoy (%) Significant subs/jvs/ associates (2) Others (1) Hyderabad cluster FY 14 FY 15 1,585 1, % 78,757 87, % 231, ,174 yoy (%) FY 14 FY 15 yoy (%) 2,032 2, % 125, , % 11.3% 397, , % Inpatient ALOS (days) Bed Occupancy Rate (%) 71% 68% 72% 67% 67% 63% 68% 63% 74% 75% Inpatient revenue (` mn) NA NA 8,372 9, % 3,763 4, % 4,573 5, % 11,901 13, % Outpatient revenue (` mn) NA NA 2,717 3, % % % 2,237 2, % 23,684 25,381 33,561 34, % 20,002 23, % 13,662 14, % 25,590 27, % NA NA 11,089 12, % 4,582 4, % 5,383 6, % 14,137 15, % ARPOB ( ` / day) (4) Total Net Revenue (` mn)(4) 7.2% Chennai & Hyderabad clusters Chennai cluster revenue growth of 12.1% Revenue growth of 8.5% in Hyderabad Others driving substantial growth (17.2%) focus on Inpatient revenue growth (17.3%). 16.6% growth in OP Revenues. Significant Subsidiary / JV & Associate Hospitals Revenue growth of 10.3%. 8% yoy growth in Bangalore & 6% yoy growth in Ahmedabad and 13% yoy growth in Kolkata. Notes: (1) Others include Madurai, Karur, Karaikudi, Trichy, Mysore, Vizag, Pune, Karimnagar, Bilaspur, Bhubaneswar, Jayanagar,Nashik & Nellore. (2) Significant Hospital JVs/Subs/Associates are Ahmedabad, Bangalore, Kolkata, Kakinada, Delhi & Indore(full revenues shown in table above). (3) Outpatient volume represents New Registrations only. (4) ARPOB and Net Revenue is net of doctor fees. (5) Revenues under the head Total have not been provided as Consolidated actual results will differ from Total due to proportionate consolidation. * Inpatient volumes are based on discharges. ** Previous year financial and operational numbers have been regrouped and reclassified wherever necessary to conform with current year classification and full year audited numbers. 24

25 ` Particulars FY 14 FY 15 Upto FY08 Batch No. of Stores Revenue/Store % EBITDA/Store % EBITDA Margin % 5.6% 5.9% 24 bps Revenue/Store % EBITDA/Store % FY09 Batch No. of Stores EBITDA Margin % yoy (%) FY 15 Revenues EBITDA ` 17,726 mn ` 580 mn ` 449 mn 30% yoy growth FY15 FY14 EBITDA Margins 3.3% 3.3% FY14 FY15 # of Stores 31 Mar 15 FY 15 Batch 242 Added 52 Closed 1,822 Total 2.9% 3.7% No. of Stores Revenue/Store % EBITDA/Store % 14.3% (yoy) 20.0% (yoy) EBITDA Margin % 4.2% 4.6% 38 bps pre FY08 batch of stores FY09 batch No. of Stores 1,632 1,822 Revenue/Store % EBITDA/Store % ROCE ~ 18% EBITDA Margin % 3.3% 3.3% 2 bps Gross addition of 53 stores and closed 15 in Q4 FY 15 13,648 17, % % 3.3% 3.3% -1 bps Capital Employed (` mn) 3,336 5,299 ROCE (Total) 9.8% 6.8% FY10 Batch Total Total Revenues EBITDA EBITDA Margin % Capex (` mn) 79 bps Like-for-like Revenue per store growth mature stores pre FY08 batch EBITDA margins 5.9% mature stores pre FY08 batch SAP revenue grew by 29.9% EBITDA margins 3.3% 25

26 26

27 well planned strategy to deliver the next phase of growth Cluster strategy for expansion with Greenfield projects in attractive newer markets We are focused on a Two pronged strategy on Healthcare services : Ensure continued dominance by expanding into key existing clusters of Chennai, Bangalore, Hyderabad, Kolkatta, Delhi and Ahmedabad Planned expansion in metros like Mumbai & large cities like Pune etc with no existing presence reaching to wider urban population Grow laterally in high potential Tier II cities Expansion through REACH hospitals, first mover advantage & leveraging the Apollo brand Increase Presence in Indian Healthcare Retail Space & calibrated expansion in Standalone Pharmacies Focus on Centers of Excellence with one or two anchor specialties in each market. Oncology a growing area across. Retail Healthcare : Increase our presence and reach across all markets through retail healthcare (Clinics, Sugar Clinics, Dental, Cradle & Dialysis) and Day Surgery centers through our Clinic subsidiary - AHLL Standalone pharmacy business - Calibrated expansion plans with focus on same store growth, increased private label sales and margin improvement Each of our key clusters besides being built around a quaternary care hospital, focus on one or two key specialties and build centers of excellence around that specialty Aim to gain significant market share in each of the key specialties Set benchmark standards in clinical outcomes, technology and practices in select acute and tertiary care services Cardiology, Oncology, Neurosciences, Critical Care, Orthopedics and Transplants (CONECT) Extend and expand our oncology presence both thru specialization and exclusive oncology referral hospitals in the clusters. 200 bedded Cancer referral center under construction in Chennai with Proton Therapy 27

28 Strong Doctor engagement Model and use of technology guided by our Clinical excellence focus Optimise Asset Utilisation in flagship facilities & locations Stabilise new facilities and compress timeto-maturity of planned capacity expansions Cost Efficiencies and Focus on Improving Key Operating Metrics Doctor engagement and Clinical focus probably is one of our core strengths. Doctor engagement model to be based on building group practice in key specialties with combination of incentives based on revenue share/ profit share Pioneers in use of technology to build robust health care systems capable of addressing diverse patient needs and changing disease profile Da Vinci Robotics in 4 locations, Truebeam, NOVALIS, Cyber Knife, PET-CT, PET-MRI, ECMO, E-ICU etc. Enhance Out-Patients focus by creating value differentiators and leveraging on personalised health checks advantage with the aim of increasing topline contribution from out-patients Garner higher market share in select acute and tertiary care services Specific plan to further penetrate deeper into Cardiology, Neurosciences & Oncology Focus on time-to-serve and service standards Bhubaneswar: Currently at 80%+ occupancy over 15% ROCE; Currently focused on: Enhancing specialization mix and adding Oncology Hyderabad and Bangalore: New capacity additions being utilised for high-end tertiary care; Recruitment of specialist consultants for COEs Shorter time-to-maturity is being planned for new facilities like: Vanagaram (260 beds), Jayanagar (140 beds), Trichy (200 beds), Nashik (100 beds), Nellore (200 beds), OMR (170 beds) Optimised asset utilisations and minimum waste of all resources thorough standardised SOP s and Lean Management Higher patient turnover by reducing average length of stay and optimised ward processes for faster turnaround time of all diagnostic process Improving average revenue per bed day through richer case mix 28

29 new projects investment & funding Location CoD* Type of Hospital No. of Beds Total Estimated AHEL s Share Project Cost of Cost (` mio) (` mio) Navi Mumbai FY16 Super Specialty 350 4,374 4,374 North Bangalore FY16 Super Specialty Vizag FY16 Super Specialty 250 1,494 1,494 MLCP FY Chennai-Main (Expansion) FY16 Super Specialty Indore (expansion) FY16 Super Specialty ,573 7, ,000 2,000 4,200 4,200 Additions in FY16 Sub Total Additions in FY19 South Chennai FY19 Super Specialty Proton FY19 Byculla, Mumbai FY19 Super Specialty 300 1,400 1,400 Patna FY19 Super Specialty 240 2,000 2, ,600 9,600 1,590 17,173 16,626 Sub Total Total Total funding requirement ` 16,626 mn (already invested ` 4,580 mn) Significant headroom to raise capital debt equity ratio 0.52x # debt EBITDA 2.48x # Gross Debt ` 16,810 mn # Cash & Cash equivalents ` 3,571 mn # Net Debt ` 13,239 mn # * Expected date of completion updated as of June 25, 2015 # Standalone financials as on 31st Mar

30 30

31 Dr. Prathap C. Reddy Executive Chairman, Founder (M.D, MBBS, FCCP, FICA and FRCS) Conferred the Padma Vibhushan in 2010 Conferred the Padma Bhushan in 1991 Spent 28 years with Apollo Hospitals Dr. Preetha Reddy Executive Vice Chairperson On the Board since the year 1989 Suneeta Reddy Managing Director On the Board since the year 2000 Shobana Kamineni Executive Vice Chairperson, on the Board since 2010 Over 20 years of experience in the healthcare industry Sangita Reddy Joint Managing Director, on the Board since 2000 Received Young Manager of the year 1998 award from Hyderabad Management Association Was a member of the Prime Minister s delegation to Malaysia organized by the CII N. Vaghul Independent Director, on the Board since 2000 Conferred the Padma Bhushan in 2009 Deepak Vaidya Independent Director, on the Board since 2000 Chairman of the Audit committee Sanjay Nayar Independent Director on the Board Vinayak Chatterjee Independent Director on the Board, Chairman of Feedback Infra Pvt Ltd Other Independent Directors G Venkatraman, Habibullah Badsha, Rafeeque Ahamed and Rajkumar Menon K. Padmanabhan Group President and has been with the company since 1996 Responsible for business and strategic initiatives across the group S. K. Venkataraman Chief Strategy Officer and has been with the company since 1991 Served as the Chief Financial Officer and Company Secretary of the Company since 2002 Responsible for strategic initiatives across the group Krishnan Akhileswaran Chief Financial Officer and has been with the Company since 2010 Over 15 years of experience in the field of Finance Responsible for the finance function of the Company and its subsidiaries Anne Marie Moncure Chief Executive Officer Southern Region Responsible for hospital operations of the Southern Region Dr. K. Hariprasad Chief Executive Officer Central Division and has been with the Company since 1999 Responsible for hospital operations for the Central Region Dr. Rupali Basu Chief Executive Officer Eastern Region and has been with the Company since 2008 Responsible for hospital operations of the Eastern Region Jacob Jacob Chief People Officer of the Company Responsible for people initiatives over 12 years of experience Arvind Sivaramakrishnan Chief Information Officer of the Company Responsible for driving IT initiatives and projects 31

32